FGF19 and metabolic dysfunction-associated steatohepatitis: Harrison et al. employed aldafermin, an FGF19 analog, to treat NASH patients [240,241], detecting a significant reduction in lipid liver content, but also a higher number of treated patients that showed fibrosis reduction and NASH resolution.